Radionuclide Imaging in Cardiac Amyloidosis: Are Nuclear Bone Tracers a Foreseeable Future?

Current Cardiovascular Imaging Reports

Volumn 8, Issue 2, 2015, Pages

  Bokhari, Sabahat ^a   Shahzad, Reehan ^a   Maurer, Mathew ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

123I MIBG; 99mTc DPD; 99mTc PYP; Cardiac amyloidosis; Nuclear imaging; Transthyretin

Indexed keywords

(3 IODOBENZYL) GUANIDINE I 123; AMYLOID; BUTEDRONATE TECHNETIUM TC 99M; FLORBETAPIR F 18; PITTSBURGH COMPOUND B; PREALBUMIN; PYROPHOSPHATE TECHNETIUM TC 99M; RADIOISOTOPE; TRACER; UNCLASSIFIED DRUG;

AMYLOID NEUROPATHY; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR PARAMETERS; DEATH; HEART AMYLOIDOSIS; HEART FAILURE; HEART TO MEDIASTINUM RATIO; HUMAN; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; RESTRICTIVE CARDIOMYOPATHY; REVIEW; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 84922309530     PISSN: 19419066     EISSN: 19419074     Source Type: Journal    
DOI: 10.1007/s12410-014-9317-6     Document Type: Review

References (40)

1. Dharmarajan K, Maurer MS. Transthyretin cardiac amyloidoses in older North Americans. J Am Geriatr Soc. 2012;60(4):765–74.
2. Desai HV, Aronow WS, Peterson SJ, Frishman WH. Cardiac amyloidosis: approaches to diagnosis and management. Cardiol Rev. 2010;18(1):1–11.
3. Dubrey SW, Cha K, Anderson J, Chamarthi B, Reisinger J, Skinner M, et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM. 1998;91(2):141–57.
4. Sultan AM, Edwards WD, Mohammed SF, et al. Cardiac amyloid deposition is common in elderly patients with heart failure and preserved ejection fraction. Circulation. 2010;122.
5. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013.
6. Cooper LT, Baughman KL, Feldman AM, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Circulation. 2007;116(19):2216–33.
7. Dubrey SW, Cha K, Skinner M, LaValley M, Falk RH. Familial and primary (AL) cardiac amyloidosis: echocardiographically similar diseases with distinctly different clinical outcomes. Heart. 1997;78(1):74–82.
8. Gertz MA, Kyle RA, Thibodeau SN. Familial amyloidosis: a study of 52 North American-born patients examined during a 30-year period. Mayo Clin Proc. 1992;67(5):428–40.
9. Ng B, Connors LH, Davidoff R, Skinner M, Falk RH. Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis. Arch Intern Med. 2005;165(12):1425–9.
10. Falk RH, Dubrey SW. Amyloid heart disease. Prog Cardiovasc Dis. 2010;52(4):347–61.
11. Macario AJ, Conway de Macario E. Sick chaperones and ageing: a perspective. Ageing Res Rev. 2002;1(2):295–311.
12. Berk JL, Suhr OB, Obici L, et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA. 2013;310(24):2658–67. This is a multicenter, randomized double-blind trial showing that the use of diflunisal in patients with ATTRm-FAP decreased progression of neurological impairment and improved quality of life after a 2-year follow-up compared to placebo. This trial reinforces the need to diagnose cardiac amyloidosis early as potential therapies may halt progression of disease.
13. Coelho T, Maia LF, Martins da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79(8):785–92.
14. Sah D. Phase I safety, pharmacokinetic and pharmacodynamics results for ALN-TTR01, a novel RNAi therapeutic for the treatment of transthyretin amyloidosis. VIIIth International Symposium on Familial Amyloid Polyneuropathy. 2011.
15. Benson MD, Pandey S, Witchell D, et al. Antisense oligonucleotide therapy for TTR amyloidosis. Amyloid. 2011;18 Suppl 1:60.
16. Coelho T, Adams D, Silva A, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013;369(9):819–29.
17. Perugini E, Guidalotti PL, Salvi F, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol. 2005;46(6):1076–84.
18. Quarta CC, Guidalotti PL, Longhi S, et al. Defining the diagnosis in echocardiographically suspected senile systemic amyloidosis. JACC Cardiovasc Imaging. 2012;5(7):755–8.
19. 99mTc-DPD can detect a cardiac amyloid with overall good sensitivity and specificity.
20. Kristen AV, Haufe S, Schonland SO, et al. Skeletal scintigraphy indicates disease severity of cardiac involvement in patients with senile systemic amyloidosis. Int J Cardiol. 2011.
21. Wizenberg TA, Muz J, Sohn YH, et al. Value of positive myocardial technetium-99m-pyrophosphate scintigraphy in the non-invasive diagnosis of cardiac amyloidosis. Am Heart J. 1982;103(4 Pt 1):468–73.
22. Gertz MA, Brown ML, Hauser MF, Kyle RA. Utility of technetium Tc 99m pyrophosphate bone scanning in cardiac amyloidosis. Arch Intern Med. 1987;147(6):1039–44.
23. Yamamoto Y, Onoguchi M, Haramoto M, et al. Novel method for quantitative evaluation of cardiac amyloidosis using (201)TlCl and (99m)Tc-PYP SPECT. Ann Nucl Med. 2012;26(8):634–43. This was the first trial using a quantitative method, “PYP score,” to distinguish heart failure due to amyloid etiologies from heart failure due to non-amyloid etiologies.
24. 99mTc-PYP is widely available in the USA and was found to have good sensitivity and specificity for identifying ATTR.
25. Nakata T, Shimamoto K, Yonekura S, et al. Cardiac sympathetic denervation in transthyretin-related familial amyloidotic polyneuropathy: detection with iodine-12-MIBG. J Nucl Med. 1995;36(6):1040–2.
26. Arbab AS, Koizumi K, Toyama K, et al. Scan findings of various myocardial SPECT agents in a case of amyloid polyneuropathy with suspected myocardial involvement. Ann Nucl Med. 1997;11(2):139–41.
27. Tanaka M, Hongo M, Kinoshita O, et al. Iodine-123 metaiodobenzylguanidine scintigraphic assessment of myocardial sympathetic innervation in patients with familial amyloid polyneuropathy. J Am Coll Cardiol. 1997;29(1):168–74.
28. Delahaye N, Dinanian S, Slama MS, et al. Cardiac sympathetic denervation in familial amyloid polyneuropathy assessed by iodine-123 metaiodobenzylguanidine scintigraphy and heart rate variability. Eur J Nucl Med. 1999;26(4):416–24.
29. Hongo M, Urushibata K, Kai R, et al. Iodine-123 metaiodobenzylguanidine scintigraphic analysis of myocardial sympathetic innervation in patients with AL (primary) amyloidosis. Am Heart J. 2002;144(1):122–9.
30. 123I-MIBG in detecting early cardiac amyloid, specifically in patients with ATTRm. This will be important with the emergence of new pharmacotherapies available for cardiac amyloid.
31. Delahaye N, Rouzet F, Sarda L, et al. Impact of liver transplantation on cardiac autonomic denervation in familial amyloid polyneuropathy. Med (Baltimore). 2006;85(4):229–38.
32. Antoni G, Lubberink M, Estrada S, et al. In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET. J Nucl Med. 2012.
33. Wall JS, Kennel SJ, Stuckey AC, et al. Radioimmunodetection of amyloid deposits in patients with AL amyloidosis. Blood. 2010;116(13):2241–4.
34. Wong DF, Rosenberg PB, Zhou Y, et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F18). J Nucl Med. 2010;51(6):913–20.
35. Cueto-Garcia L, Tajik AJ, Kyle RA, et al. Serial echocardiographic observations in patients with primary systemic amyloidosis: an introduction to the concept of early (asymptomatic) amyloid infiltration of the heart. Mayo Clin Proc. 1984;59(9):589–97.
36. Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation. 2005;112(13):2047–60.
37. Sun JP, Stewart WJ, Yang XS, et al. Differentiation of hypertrophic cardiomyopathy and cardiac amyloidosis from other causes of ventricular wall thickening by two-dimensional strain imaging echocardiography. Am J Cardiol. 2009;103(3):411–5.
38. Penugonda N. Cardiac MRI in infiltrative disorders: a concise review. Curr Cardiol Rev. 2010;6(2):134–6.
39. Kwong RY, Falk RH. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2005;111(2):122–4.
40. Karamitsos TD, Piechnik SK, Banypersad SM, et al. Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging. 2013;6(4):488–97.